Cysteine cathepsins are lysosomal enzymes expressed in the kidneys and other tissues, and are involved in the maturation and breakdown of cellular proteins. They have been shown to be integrally involved in the progression of many cardiovascular and renal diseases. The goal of this study was to determine the involvement of cysteine cathepsins in the development of salt‐sensitive hypertension and associated kidney damage. In our experiments, Dahl salt‐sensitive (SS) rats were fed an 8% high salt NaCl diet and intravenously infused with the irreversible cysteine cathepsin inhibitor E‐64 (1 mg/day) or the vehicle (control). Both the control and E‐64 infused groups developed significant hypertension and kidney damage, and no difference of the mean arterial pressure and the hypertension‐associated albuminuria was observed between the groups. We next tested basal calcium levels in the podocytes of both control and infused groups using confocal calcium imaging. Basal calcium did not differ between the groups, indicative of the lack of a protective or aggravating influence by the cathepsin inhibition. The efficacy of E‐64 was tested in Western blotting. Our findings corresponded to the previously reported, E‐64 induced increase in cathepsin B and L abundance. We conclude that the inhibition of cysteine cathepsins by E‐64 does not have any effects on the blood pressure development and kidney damage, at least under the studied conditions of this model of SS hypertension.
Cathepsins (Cath) are proteolytic enzymes that are important in such cellular functions as the breakdown, maturation, and modulation of the bioactivity of proteins. Three major groups of Caths have been categorized: syrine (A and G), aspartic (D and E), and cysteine Caths. Cystein Caths, members of the family of papain‐like cysteine proteases, are the largest Cath family in humans that is comprised of 11 proteases (the Caths B, C, F, H, K, L, O, S, V, X and W) (Turk et al. 2012). These enzymes, which are stable in acidic environments, are primarily found in lysosomes and endosomes. However, active forms and splice variants can be found in the extracellular (Reddy et al. 2001; Jaiswal et al. 2002), cytosolic, mitochondrial (Muntener et al. 2004), and nuclear compartments (Goulet et al. 2004; Alcalay et al. 2008).
Cath B and L are among the most abundant lysosomal proteases (Rossi et al. 2004). Both Cath B and L are endopeptidases, however Cath B contains an occluding loop (Musil et al. 1991) that blocks the active site and prevents endopeptidase activity at low pH levels. At less acidic pH, the loop opens, enabling Cath B endopeptidase activity (Illy et al. 1997). Both Cath B (Kominami et al. 1985) and L (Sever et al. 2007) are abundantly expressed within the kidney and Cath L expression has been shown to be strongly associated with the extent of renal injury (Bauer et al. 2011). How these and other Caths contribute to a variety of diseases has been of recent interest.
Previous studies have shown beneficial in vivo effects of cysteine Cath inhibition in several disease models. These include chronic kidney disease (Bauer et al. 2011; Fox et al. 2016), hypertensive heart failure (Cheng et al. 2008), and polycystic kidney disease (Igarashi and Somlo 2007; Alcalay et al. 2008). However, cysteine Cath inhibition in the context of salt‐sensitive (SS) hypertension has yet to be studied. SS hypertension is characterized by an elevated mean arterial pressure (MAP), associated kidney damage, and proteinuria caused by a high salt (HS) diet. Previous use of Cath inhibitors in disease models suggests that multiple Caths may contribute synergistically to disease progressions and the use of a nonspecific Cath inhibitor may be a more effective approach (Siklos et al. 2015). Thus, E‐64, a nonspecific inhibitor, was used to asses cysteine Cath function in SS hypertension.
The effacement of glomerular podocytes, which are essential for the glomerular filtration barrier (Pavenstadt et al. 2003), can cause proteinuria (Nagase et al. 2006). Previously, the in vitro inhibition of renal cysteine Caths was shown to attenuate this effacement (Sever et al. 2007; Faul et al. 2008). However, whether this observation will extend to the in vivo inhibition and other pathophysiological effects of SS hypertension has yet to be determined. Sustained Ca2+ overload in glomerular podocytes was also previously indicated as a driving factor of the podocyte effacement (Lavin and Winn 2011). Therefore, the study here measured E‐64 induced changes of glomerular podocyte basal [Ca2+]i in SS rats. Overall, the goal of the study was to identify whether the in vivo inhibition of cysteine Caths attenuates SS hypertension, and the coupled proteinuria and kidney damage.
Material and Methods
Animal use and welfare adhered to the NIH Guide for the Care and Use of Laboratory Animals following a protocol reviewed and approved by the IACUC of the Medical College of Wisconsin. Seven‐week old male Dahl Salt Sensitive rats (SS/JrHsdMcwi) were used. Food (0.4% or 8.0% NaCl AIN‐76 purified rodent food; Dyets, Bethlehem, PA) and water were provided ad libitum. Animals were housed in metabolic cages 7 days prior to femoral artery and vein catheterization. They were then returned to the metabolic cages and allowed to recover from surgery for 5–7 days.
Chronic instrumentation for venous infusion and blood pressure measurement
Chronic instrumentation of rats for venous infusion and blood pressure measurements was done as described previously. Briefly, 8‐week old anesthetized SS rats had their left femoral artery and vein catheterized. Both catheters were fixed and exteriorized from the back of the neck and the arterial line was connected to a heparinized saline infusion pump that was in line with a blood pressure transducer, and the venous line was connected to a saline infusion pump. Animals were allowed 360° movement using a tether‐swivel system. This preparation allowed chronic venous infusion and arterial blood pressure measurement in conscious, freely moving rats. A stable baseline blood pressure was obtained for 4 days prior to switching both groups to an 8.0% NaCl diet and the simultaneous addition of N‐[N‐(L‐3‐trans‐carboxyox‐irane‐2‐carbonyl)‐L‐leucyl]‐agmatine (E‐64, 1 mg/day; 280 mmol/L stock in DMSO; ApexBio, Houston, TX, Cat #A2576) or the vehicle (DMSO in saline) control to the venous catheter. Daily MAP was calculated by averaging MAP taken every min over the beginning 3 h period of the rat sleep cycle.
Blood and urine electrolyte measurement
By detaching the femoral arterial catheter from the swivel, 1 mL of arterial blood was collected the morning of the diet change and at every subsequent 7th day. Twenty‐four hour urine was collected with the metabolic cage apparatus on the same day as blood collections. Whole blood and urine electrolytes were measured with a blood gas and electrolyte analyzer (ABL system 800 Flex; Radiometer, Copenhagen, Denmark). Albumin was measured using a fluorescent assay (Albumin Blue 580 dye; Molecular Probes, Eugene, OR), read by a fluorescent plate reader (FL600; Bio‐Tek, Winooski, VT), and creatinine using a Jaffé reaction‐assay using an autoanalyzer (ACE; Alfa Wasserman, West Caldwell, NJ). Inorganic phosphorus was measured by chemical reduction to form a phosphomolybdate complex (P7516; Pointe Scientific, Canton, MI) and read by a fluorescent plate reader (SpectraFluor Plus; Tecan). Ammonia was quantified using an enzymatic reagent kit (A7553; Pointe Scientific) and read by a fluorescent plate reader (SpectraFluor Plus; Tecan, Männedorf, Switzerland).
Rats were anesthetized, and their descending aortas were catheterized. Kidneys were flushed via the catheter with PBS (3 mL/min/kidney) until blanched. Kidneys were excised and decapsulated. Half of the right kidney was used for glomerular podocyte basal [Ca2+]i measurements and the other half was used for Western blot analysis. The left kidney was used for histochemistry staining.
Histochemistry and Western blot analysis
Rat kidneys were fixed in zinc formalin, paraffin embedded, sectioned, and mounted on slides. Slides were stained with the Masson's trichrome stain. Renal cortical protein levels were determined by immunoblotting on unfixed, frozen samples with antibodies for Cath B (sc‐6493; Santa Cruz, Dallas, TX) and Cath L (sc‐6498; Santa Cruz). Kidney cortical sections were isolated and then lysed. Equal amounts of cell lysate were subjected to Western blot analysis with the Cath antibodies and β‐actin as was previously described (Karpushev et al. 2011).
Isolation of glomeruli and measurement of podocyte basal [Ca2+]i
Isolation and basal podocyte [Ca2+]i measurements were done as has been previously reported (Ilatovskaya and Staruschenko 2013; Ilatovskaya et al. 2015b). Briefly, the kidney cortex was mechanically isolated and minced until homogenous. The minced tissue was pushed through a 100 followed by a 140 mesh sieve. The flow‐through was filtered by a 200 mesh sieve and the sieve‐sedimented glomeruli were collected. Isolated glomeruli were incubated with Fura Red, AM and Fluo‐4, AM (5 μmol/L; Invitrogen, Grand Island, NY) for 40 min at room temperature. Glomeruli were adhered to poly‐l‐lysine coated glass coverslips and imaged using a confocal laser‐scanning microscope.
Calcium imaging was performed as has been previously described (Ilatovskaya and Staruschenko 2013; Ilatovskaya et al. 2014, 2015a,b). A laser‐scanning confocal microscope system (Nikon A1‐R, NIS Elements; Nikon Instruments Inc, Tokyo, Japan) was used to collect images in time series (xyt, 4 s per frame). Basal [Ca2+]i of podocytes were measured after stable fluorescence intensities were established. Only surface podocytes of glomeruli were recorded. Each experiment measured basal [Ca2+]i of 4 to 9 podocytes of at least one glomerulus imaged.
Data are presented as mean ± SEM. The MAP, blood, and urine measurements were compared using the two‐way analysis of variance (ANOVA) for repeated measures followed by the Holm–Sidak post hoc test. For the podocyte calcium measurements, the values of [Ca2+]i at every moment of time for individual cells were averaged by the number of regions registered in the experiment. Data for kidney/TBW ratios, podocyte calcium measurements, and the relative Cath protein levels were compared using the independent‐samples t‐test. P values less than 0.05 were considered significant.
Mean arterial pressure of catheterized SS rats
Basal MAP was recorded for 4 days prior to the switch of diets to 8.0% NaCl and the addition of 1 mg/day of E‐64 to venous infusate. Figure 1 illustrates the typical progressive increase in the rat MAP induced by the 21 day 8.0% NaCl diet (Moreno et al. 2011; Endres et al. 2014; Cowley et al. 2016). The E‐64 treatment did not attenuate MAP (P = 0.239, two‐way ANOVA) and kidney weights were similar between E‐64 treated (M = 1.440 ± 0.051) and the control group (M = 1.454 ± 0.044) (P = 0.857, independent‐sample t‐test; data not shown).
Blood electrolyte concentrations are shown in Figure 2. SS rats fed an 8.0% NaCl diet had significantly reduced blood [K+] in the first 7 days on the diet that continued through the remainder of the diet (P < 0.001, two‐way ANOVA). [Ca2+] gradually decreased during the 21 day diet (P < 0.001, two‐way ANOVA). However, no significant change was observed for [Na+] and [Cl−]. All measured blood electrolyte concentrations were no different between the two groups.
Urinary output, electrolytes, and albumin, phosphorus, and ammonia/creatinine ratios
An 8.0% NaCl diet induced a significant increase in the daily urine volume by day 7 that continued for the following 14 days (P < 0.001, two‐way ANOVA), and a steady, significant increase in albuminuria (normalized to creatinine) was observed during the 21 days of the HS diet compared to day 0 (P < 0.01, two‐way ANOVA) (Fig. 3A). Of the urine electrolytes measured (Fig. 3B), K+ (P < 0.01), Na+, Ca2+, and Cl− excretion significantly increased after day 0 (normalized to creatinine, P < 0.001, two‐way ANOVA). Urinary phosphorus significantly increased after day 0 (P < 0.001, two‐way ANOVA) (Fig. 4A). Urinary ammonia did not significantly increase (Fig. 4B) and no difference was found between the groups of all urine measurements.
E‐64 effect on glomeruli and podocytes
Taking into consideration that E‐64 inhibition of Caths has been shown to attenuate glomerular damage, histological coronal sections of the kidneys were done. Figure 5 shows representative renal and glomeruli damage observed in SS rats after the 21 days of an 8.0% NaCl diet. The E‐64 infused rats had no observable change in glomeruli damage. Basal [Ca2+]i has been shown to be linked with podocyte dysfunction. Here, we measured basal [Ca2+]i of podocytes in freshly isolated glomeruli (Fig. 6). The E‐64 treated rats had no difference in basal podocyte [Ca2+]i (P = 0.429, independent‐sample t‐test).
Cathepsin B and L expression
Previously, inhibition of cysteine Caths by E‐64 has been shown to increase the half‐lives of cysteine Caths due to the requirement of functional cysteine Caths for their degradation (Kominami et al. 1987; Katunuma 2010). This provides a useful tool to assess whether in vivo administration E‐64 was effective at inhibiting Caths in the renal tissue. Specifically, Cath B and L kidney abundance was measured as they are two primary targets of E‐64 (Hashida et al. 1982). A significant increase in the renal cortical mature form of Cath B (Fig. 7A) and Cath L (Fig. 7B) were measured in E‐64 treated rats (P < 0.01, independent‐sample t‐test). The pro Cath L abundance was not different between the groups and pro Cath B was not detected.
The goal of this study was to identify whether cysteine Caths modulate the development of SS hypertension and kidney injury in vivo. Multiple studies previously identified that cysteine Caths play a role in the pathogenesis of kidney diseases mostly by their proteolytic activities. For instance, as summarized by Kistler et al. (2010), many glomerular diseases can be regarded as podocyte enzymatic disorders. In addition to the cysteine Cath function in glomeruli, they have been shown to be involved in tubular transport and other processes in the kidney. However, the role of cysteine Caths in the development of hypertension in vivo remains to be determined. We provide evidence here that both the increased MAP and the corresponding kidney damage observed in Dahl SS rats fed a HS diet were not significantly affected by the long‐term E‐64 treatment. Despite the absence of an effect of Cath inhibition on the progression of HS‐induced hypertension, the inhibitor dosage used was sufficient to increase the renal cortical level of mature Cath B and L. As has been previously reported, the increased mature Cath levels suggest that the E‐64 inhibition of Caths impairs their autodegradation. Therefore, E‐64 irreversibly inhibited renal cysteine Caths, but this did not induce any measured changes in the expected pathophysiology of SS hypertension.
Cytoplasmic Cath L has been shown to be required for the induction of proteinuria in mice. Its role is to cleave intracellular proteins involved in the regulation of the podocyte actin cytoskeleton (Reiser et al. 2004; Sever et al. 2007; Faul et al. 2008). Podocytes will then retract their foot processes that may result in podocyte effacement. However, our data revealed that Cath inhibition by the studied E‐64 dose in this particular model had no effect on the HS‐induced podocyte dysfunction and albuminuria. Recently, Cath D has been shown to be important in this process (Yamamoto‐Nonaka et al. 2016). Cath D belongs to the aspartyl group of Caths. Thus, E‐64, used in this study, would not have inhibited Cath D and its function in SS hypertension proteinuria. Interestingly, Cath B and L have been shown to be involved in the regulation of Cath D (Wille et al. 2004; Laurent‐Matha et al. 2006; Zheng et al. 2008), which might explain this inconsistency between our and the previously reported data.
The role of cysteine Caths in auto activation and degradation, as is present in most other Caths, is well known (Kominami et al. 1987; Katunuma 2010). Previously, Caths were viewed as redundant but newer evidence has revealed that each type has specific functions as well as some being subcellularly isolated from each other. The increased mature Cath L in the E‐64 treated group but not in the proform supports that E‐64 causes increased half‐lives of mature Caths by impairing their autodegradation and not their increased activation or expression of Caths. However, the increased protein level of Cath B and Cath L does not indicate the extent of E‐64 inhibition of either Caths. While the E‐64 inhibition of Cath B and L are likely based on E‐64's Cath affinities and the characteristic Cath autodegradation dysfunction, impaired Cath degradation does not indicate that Cath B and L were the primary targets of E‐64. Alternative proteases that are currently unknown to be involved in Cath B and L degradation might have been more inhibited by E‐64. Therefore, an increased catalytic activity is a possible interpretation of the increased renal Cath B and L protein level.
The proteinuria we observed in the SS rats fed a HS diet was expected to be attenuated by E‐64 treatment. In cultured podocytes, E‐64 was recently reported to block an Ang II‐induced, STAT3 mediated loss of the cytoskeleton regulatory protein synaptopodin (Abkhezr and Dryer 2015). The absence of attenuated albuminuria suggests that cysteine Caths are not involved in the development of SS hypertension‐associated proteinuria. Furthermore, the basal podocyte [Ca2+]i was similar to previously reported levels (Ilatovskaya et al. 2015a).
Another potential mechanism, which might modulate the development of SS hypertension by cysteine Caths, is the control of the epithelial Na+ channel (ENaC)‐mediated sodium absorption in the collecting ducts. ENaC is the main sodium transporter in the aldosterone‐sensitive distal nephron (Staruschenko 2012) and its activity significantly contributes to the development of salt‐induced hypertension in Dahl SS rats (Aoi et al. 2006; Kakizoe et al. 2009; Pavlov et al. 2013). It is well established that activity of ENaC is enhanced by proteolytic cleavage (Bruns et al. 2007; Svenningsen et al. 2009; Ray and Kleyman 2015; Zachar et al. 2015). It was also reported that the cysteine protease Cath S can activate ENaC which may be relevant under pathophysiological conditions (Haerteis et al. 2012). Similarly, other Caths, such as Caths B, H, and S, were shown to modulate ENaC activity in both kidneys and lungs (Alli et al. 2012; Tan et al. 2014; Evans et al. 2016). Considering that Caths are precisely modulated under physiological and pathophysiological conditions, as was shown for Cath D that is significantly altered in response to the activation of the vasopressin signaling (Pisitkun et al. 2006), E‐64 may also be expected to have some effects on the development of SS hypertension via its effects on ENaC activity. However, changes in electrolyte excretion would have been expected but was not observed in the E‐64‐treated animals.
We have shown here evidence that E‐64 does not affect either the blood pressure control or kidney injury in Dahl SS rats fed a HS diet. This might indicate that cysteine Caths are not involved in the progression of SS hypertension. Alternatively, other Caths and cellular proteases may be involved in SS hypertension and kidney damage. Our findings indicate that in vivo inhibition of cysteine Caths may be an ineffective method of attenuating SS hypertension as was indicated by the increased renal Cath B and L protein levels and the lack of attenuated pathophysiology. Likewise, the interregulation of Caths may offset any beneficial inhibitory affects. Future studies using more selective Cath inhibitors may be needed to identify in vivo Cath functions in SS hypertension.
Conflict of Interest
There are no conflicts of interests.
We would like to thank Jessica L. Barnett for help with data analysis and Christine Duris for histology experiments.
This research was supported by the National Institutes of Health grants HL10880, HL122662 (to AS), and DK105160 (to DI), the American Diabetes Association grant 1‐15‐BS‐172, and the American Heart Association (16EIA26720006) (to AS).
- Manuscript Received: May 27, 2016.
- Manuscript Revised: August 8, 2016.
- Manuscript Accepted: August 10, 2016.
- © 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of the American Physiological Society and The Physiological Society.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.